Licensing deal gives iOnctura exclusive global development rights to novel TGFβ pathway inhibitor IOA-359 Pipeline expansion builds on iOnctura’s strategy of targeting multiple cancer survival pathways with a single drug; in this case targeting therapy resistance and immune evasion…